Price of pain: Population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia

Journal of Pain Research

Volumn 9, Issue , 2016, Pages 543-550

  Friesen, Kevin J ^a   Falk, Jamie ^a   Alessi Severini, Silvia ^a   Chateau, Dan ^a   Bugden, Shawn ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cost; Economics; Gabapentin; Neuropathic pain; Shingles

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; GABAPENTIN; GLUCOCORTICOID; LOCAL ANESTHETIC AGENT; NABILONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREGABALIN;

ARTICLE; CANADA; COHORT ANALYSIS; DRUG COST; HERPES ZOSTER; HUMAN; ICD-10; ICD-9; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORBIDITY; OBSERVATIONAL STUDY; POPULATION RESEARCH; POSTHERPETIC NEURALGIA; PRESCRIPTION; RETROSPECTIVE STUDY;

EID: 84983288532     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S107944     Document Type: Article

References (30)

1. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(02):305-314.
2. Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109-120.
3. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1): S1-S26.
4. Bennett G, Watson C. Herpes zoster and postherpetic neuralgia: past, present and future. Pain Res Manag. 2009;14(4):275-282. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2734513/. Accessed November 18, 2015.
5. Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68(7):900-918.
6. Tontodonati M, Ursini T, Polilli E, et al. Post-herpetic neuralgia. Int J Gen Med. 2012;5:861-871.
7. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38-47.
8. Ultsch B, Köster I, Reinhold T, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2013;14(6):1015-1026.
9. Weitzman D, Shavit O, Stein M, Cohen R, Chodick G, Shalev V. A population based study of the epidemiology of herpes zoster and its complications. J Infect. 2013;67(5):463-469.
10. Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine. 2011;29(47):8580-8584.
11. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23-24):3076-3090.
12. Cebrián-Cuenca AM, Díez-Domingo J, San-Martín-Rodríguez M, PuigBarberá J, Navarro-Pérez J. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis. 2011;11(1):302.
13. Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.
14. Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-335.
15. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010; 17(9):1113-e88.
16. Boivin G, Jovey R, Elliott CT, Patrick DM. Management and prevention of herpes zoster: a Canadian perspective. Can J Infect Dis Med Microbiol. 2010;21(1):45-52.
17. Philip A, Thakur R. Post herpetic neuralgia. J Palliat Med. 2011;14(6): 765-773.
18. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125-132.
19. Roos LL, Brownell M, Lix L, Roos NP, Walld R, Macwilliam L. From health research to social research: privacy, methods, approaches. Soc Sci Med. 2008;66:117-129.
20. Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86(12):1146-1153.
21. Statistics Canada. Annual Demographic Estimates: Canada, Provinces and Territories. Ottawa, ON: Statistics Canada; 2015.
22. O’Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc. 2007;55(8):1176-1184.
23. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice ASC. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):0628-0644.
24. Drug Products Database. Heal Canada Website. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp. Accessed November 2, 2015.
25. Torborg DS. The dark side of the boom: the peculiar dilemma of modern False Claims Act litigation. J Law Health. 2013;26:181-218.
26. National Opioid Use Guideline Group. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain-Part A Executive Summary. 2010:1-38. Available from: http://nationalpaincentre. mcmaster.ca/documents/opioid_guideline_part_a_v4_5.pdf. Accessed April 25, 2016.
27. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13-21.
28. Bilcke J, Ogunjimi B, Marais C, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096-2109.
29. Di Legami V, Gianino MM, Atti MCD, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007;25(43):7598-7604.
30. Lionis CD, Vardavas CI, Symvoulakis EK, et al. Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece. BMC Fam Pract. 2011;12(1):136